DexCom Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 7,000 shares of DexCom stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $81.87, for a total value of $573,090.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin R. Sayer also recently made the following trade(s):

  • On Wednesday, September 14th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The stock was sold at an average price of $91.79, for a total value of $642,530.00.
  • On Monday, August 15th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The stock was sold at an average price of $90.78, for a total value of $635,460.00.

DexCom Inc. (NASDAQ:DXCM) opened at 81.97 on Tuesday. The stock’s market cap is $6.88 billion. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The company’s 50-day moving average price is $89.38 and its 200-day moving average price is $78.86.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The firm had revenue of $137.30 million for the quarter, compared to analyst estimates of $132.48 million. During the same period in the previous year, the company earned ($0.05) EPS. DexCom’s revenue was up 47.3% compared to the same quarter last year. On average, equities analysts expect that DexCom Inc. will post ($0.57) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Several institutional investors have recently made changes to their positions in the stock. Private Bank & Trust Co. purchased a new position in shares of DexCom during the third quarter worth approximately $220,000. Capstone Asset Management Co. purchased a new position in shares of DexCom during the third quarter worth approximately $205,000. BNP Paribas Arbitrage SA boosted its position in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares during the last quarter. Eqis Capital Management Inc. boosted its position in shares of DexCom by 5.3% in the third quarter. Eqis Capital Management Inc. now owns 7,628 shares of the medical device company’s stock worth $669,000 after buying an additional 382 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its position in shares of DexCom by 60.2% in the second quarter. Macquarie Group Ltd. now owns 221,340 shares of the medical device company’s stock worth $17,559,000 after buying an additional 83,185 shares during the last quarter. 99.28% of the stock is owned by institutional investors and hedge funds.

A number of research firms have issued reports on DXCM. B. Riley began coverage on DexCom in a research note on Monday, September 26th. They issued a “neutral” rating and a $97.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and issued a $92.00 price objective on shares of DexCom in a research note on Thursday, August 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research note on Wednesday, July 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $93.00 price objective on shares of DexCom in a research note on Friday, July 15th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a report on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $95.40.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.